Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists

  title={Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists},
  author={Michael Poyurovsky and Abraham Weizman},
  pages={871 - 882}
Akathisia is one of the most prevalent and distressing adverse effects associated with antipsychotic drug treatment. Propranolol, a non-selective beta-adrenergic receptor antagonist, is currently considered a first-line treatment for antipsychotic-induced akathisia (AIA). Surprisingly, the evidence for its anti-akathisia effect is modest. Propranolol’s side effects (e.g. orthostatic hypotension, bradycardia), contraindications (e.g. asthma) and increased complexity in titration schedules limit… Expand
Manage antipsychotic-induced akathisia by making changes to the antipsychotic drug regimen and/or adding anti-akathisia agents
Patients should first receive an adjustment in their antipsychotic drug regimen, and if further intervention is needed, propranolol is considered as the first-choice anti-akathisia agent. Expand
Case of aripiprazole long‐acting‐related akathisia successfully managed with carvedilol: A case report
The author has not received research support or speakers’ honoraria from, or has served as a consultant to, Sumitomo Dainippon, Otsuka, DAIICHI SANKYO, Tsuruma, Nihon Medi-Physics and Pfizer. Expand
Recommendations of the schizophrenia expert center network for the screening prevention and treatment of sleep disorders based on the results from the real-world schizophrenia FACE-SZ national cohort
BACKGROUND Sleep disorders associated factors are under explored in schizophrenia while the literature suggests high and heterogeneous frequency. AIMS The objective of the present study was toExpand


Treatment of Neuroleptic-Induced Akathisia With the 5-HT2A Antagonist Trazodone
Trazodone is found to be a beneficial and relatively safe medication for the treatment of antipsychotic medication-induced akathisia and some improvement was noted in symptomatology of anxiety, depression, and psychosis. Expand
Lack of efficacy of the 5-HT3 receptor antagonist granisetron in the treatment of acute neuroleptic-induced akathisia.
It seems that the 5-HT3 subtype of serotonergic receptor is not involved in the development of NIA, and 5- HT3 antagonists are ineffective in the serotonin-related pharmacotherapy of Nia. Expand
Trazodone for the Treatment of Neuroleptic-Induced Acute Akathisia: A Placebo-Controlled, Double-Blind, Crossover Study
It is suggested that Trz's property of serotonin 2A postsynaptic receptor antagonism may be its principal mechanism for the improvement of NIA. Expand
Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin.
First results of a single-blind trial of ritanserin in the treatment of neuroleptic-induced akathisia are encouraging and warrant further studies. Expand
SSRI-Induced extrapyramidal side-effects and akathisia: implications for treatment
  • R. Lane
  • Psychology, Medicine
  • Journal of psychopharmacology
  • 1998
It is important that the rare occurrence of EPS in patients receiving SSRIs does not preclude their use in Parkinson's disease where their potentially significant role requires more systematic evaluation. Expand
The Role of Serotonin in Antipsychotic Drug Action
  • H. Meltzer
  • Psychology, Medicine
  • Neuropsychopharmacology
  • 1999
Future antipsychotic drug development can include targeting multiple serotonin receptor subtypes, some, or all of which, may contribute to their differences in efficacy and side effect profile. Expand
5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis.
The findings suggest that 5-HT(2A) antagonists are effective in the treatment of NIA and should be considered as a first-line treatment for neuroleptic-induced akathisia. Expand
Low-Dose Mirtazapine: A New Option in the Treatment of Antipsychotic-Induced Akathisia. A Randomized, Double-Blind, Placebo- and Propranolol-Controlled Trial
The comparable efficacy and better tolerability of low-dose mirtazapine versus propranolol, the current first-line treatment for AIA, position mirtzapine as a favorable candidate for the treatment of acute AIA and may improve current therapeutic practices. Expand
Serotonergic agents in the treatment of acute neuroleptic‐induced akathisia: open‐label study of buspirone and mianserin
It seems that the 5-HT1A partial agonist buspirone is of limited value in the treatment of acute neuroleptic-induced akathisia, and in contrast, it appears that low-dose mianserin is therapentically effective in acute neuroLEptic- induced akath isia. Expand
Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study.
Mianserin at a low dose may be a promising therapeutic option for patients with acute neuroleptic-induced akathisia, as well as by other relevant clinical rating scales. Expand